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ABSTRACT
OBJECTIVE: The objective of this selective EBM review is to determine whether or not
itraconazole is effective in the treatment of patients diagnosed with tinea versicolor and if so,
what is the optimal dosage.
STUDY DESIGN: Review of three peer-reviewed, randomized control trials (RCTs), two of
which were published in 2002 and one in 2010.
DATA SOURCES: Studies were researched through PubMed and selected based on the type of
study (RCT), their relevance to the clinical question, and if they were POEMS (patient oriented
evidence that matters).
OUTCOME(S) MEASURED: Patient’s subjective measurement of the severity of pruritis,
erythema, scaling, and pigment changes after treatment. Outcomes were also measured by a
Wood’s lamp examination and a KOH preparation.
RESULTS: Itraconazole was shown to be effective in treating tinea versicolor both clinically and
mycologically. Patients reported a decrease in scaling, pigment changes, and pruritis, and their
Wood’s lamp examination and KOH preparation were also negative. Of the two studies that
reported p-values, one showed that the results were statistically significant (p <0.001) and the
other showed the opposite (p>0.05).
CONCLUSIONS: All three studies showed that itraconazole produced favorable results in the
treatment of tinea versicolor and a single dose was an effective alternative to a seven day
regimen. A single dose is also more advantageous because of decreased cost and increased
compliance. Itraconazole is also effective as prophylaxis for tinea versicolor when taken one day
each month.
KEY WORDS: itraconazole, tinea versicolor
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INTRODUCTION
Tinea versicolor, also known as pityriasis versicolor, is a chronic superficial fungal
infection of the skin, most commonly occurring on the upper trunk. It is caused by Malassezia
which is a normal colonizer of human skin. When Malassezia grows in excess on the skin, it can
lead to this infection.1 Risk factors for the overgrowth of Malassezia include warm, humid
environments, immunosuppression, malnutrition, corticosteroid usage, and possibly a genetic
predispostion.2 Although tinea versicolor is considered a chronic infection with high rates of
reoccurrence, there are both topical and systemic treatments available to either eradicate the
current infection or serve as prophylaxis. This paper evaluates three randomized control trials
(RCTs) comparing either two doses of itraconazole or itraconazole versus a placebo to determine
which is more efficacious in the treatment of tinea versicolor.
Tinea versicolor affects people worldwide, and it is most common in the tropical
climates, due to warm, humid environments being a risk factor for the overgrowth of Malassezi.
In the US the prevalence of tinea versicolor is estimated to be 2-8%. The precise number is
unknown because most people do not seek medical attention when this infection occurs.2 The
annual health care cost of tinea versicolor is unavailable. Due to the broad spectrum of fungal
infections that intraconazole is used to treat, there is no data regarding the annual cost of
itraconazole in the treatment of tinea versicolor. The most recent data published regarding the
amount of health care visits per year for tinea versicolor infections was in 2004, in which there
were approximately 2.9 million visits in the US alone.3
Tinea versicolor affects all races, although it is more apparent in darker skinned
individuals and it is most common in the age range of 15-24 years old due to increased activity
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of sebaceous glands.2 The infection may be asymptomatic but in some patients, the symptoms
that capture their attention include tan, pink, or white colored macules that do not tan in the
summertime and pruritis. The macules have scales and may be located anywhere on the body but
they are most commonly seen on the trunk. Tinea versicolor is not contagious because it is a
normal pathogen of human skin. This infection is considered benign; therefore there is no
significant morbidity and mortality.2 Most patients will experience reoccurrences of this
infection, with rates reaching as high as 60% within one year and 80% within two years.4
There are many treatments available to treat tinea versicolor including both topical and
systemic agents. Some of the topical agents include selenium sulfide shampoo, ketoconazole
shampoo, zinc pyrithione shampoo, miconazole, clotrimazole, terbinafine, salicylic acid, and
benzyl peroxide. Systemic agents include ketoconazole, fluconazole, and itraconazole.1, 2, 5
Although itraconazole is already being used to treat tinea versicolor, the researchers
wanted to compare the effectiveness of a single dose versus a seven day treatment because it
would allow for a decreased cost and increased compliance. Also the researchers wanted to look
at itraconazole as a prophylactic agent for tinea versicolor due to the high rates of reoccurrence.
OBJECTIVE
The objective of this selective EBM review is to determine whether or not itraconazole is
effective in the treatment of patients diagnosed with tinea versicolor and if so, what is the
optimal dosage.
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METHODS
Certain criteria were used to select appropriate studies on this topic. This criteria included
a population of patients who were clinically diagnosed with tinea versicolor by a Wood’s lamp
examination or by KOH preparation, and the majority of patients were over 18 years old, nonpregnant, and had not been using an antifungal treatment. The interventions in these studies
included the use of itraconazole 400mg for one day or itraconazole 200mg BID one day per
month for six months. In two of the articles, comparisons were made between the treatment
group which received itraconazole 400mg for one day versus the control group who received
itraconazole 200mg for seven days. In the last article, itraconazole 200mg BID one day per
month for six months was given to the treatment group and compared to the control group which
received placebo pills BID one day per month for six months. Outcomes measured the efficacy
of itraconazole in the curative treatment of tinea versicolor which was based off of decreased
pruritis, scaling, and hypopigmentation.
All three of the studies were RCTs that were published in peer-reviewed journals and in
the English language, with one of the studies being double blinded. Key words utilized to search
for these RCTs included “itraconazole” and “tinea versicolor”. The articles were researched
through PubMed and selected based on the type of study (RCT), their relevance to the clinical
question, and if they were POEMS (patient oriented evidence that matters). The inclusion criteria
included RCTs published after 1996 and patients who were clinically diagnosed with tinea
versicolor by a Wood’s lamp examination or KOH preparation. Exclusion criteria varied among
the studies but included criteria such as age <18 years old, pregnant women, and the use of
antifungals prior to the study. The full exclusion criteria can be seen in Table 1. A summary of
the statistics reported or used in the trials include RBI, ABI, NNT, and p-values.
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Table 1: Demographics & characteristics of included studies
Study
Type
# Pts Age (yrs)
Inclusion
Exclusion criteria
criteria
Kose
RCT
50
For
Diagnosis of
Age <18yrs;
4
(2002)
experimental
tinea versicolor women of
group: 20 +
based off of a
childbearing age;
41
positive KOH
no systemic
For control
solution and
antifungal intake
group: 21 +
Wood’s lamp
prior to the study
38
exam

W/D

Interventions

0

Use of
itraconazole
400mg
x1day
compared to
control
group using
itraconazole
200mg x7d
Use of
itraconazole
400mg
x1day
compared to
control
group using
itraconazole
200mg x7d
Prophylactic
treatment:
Itraconazole
200mg OR
Placebo BID
1 day per
month x6
months

Wahab
(2010)5

RCT

60

Group A: 32
+9
Group B: 33 +
8

Diagnosis of
tinea versicolor
based off of a
Wood’s lamp
exam and KOH
solution

Age <18 yrs;
pregnancy and
topical and
systemic
antifungal agents;
localized lesions,
serious systemic
illness

0

Faerge
mann
(2002)6

Double
blind
RCT

209

Group A
(itraconazole):
12-62, avg 30
Group B
(placebo): 1265, avg 30

12-70 yrs old
with a diagnosis
of tinea
versicolor
confirmed by
mycological
exam

Pts with: known
sensitivity to
itraconazole,
chronic
mucocutaneous
candidiasis or
systemic fungal
infection,
immunosuppressio
n, any other
disease in the
investigators’
opinion should
exclude the pt,
participated in
drug trial within
30 days, pregnant
or breastfeeding,
women of
childbearing
potential without
adequate
contraception

4
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OUTCOMES
The outcomes measured in these studies were POEMS, which included the patient’s
subjective measurement of the severity of pruritis, erythema, scaling, and pigment changes. They
were also measured by the investigator which was based off of a negative Wood’s lamp
examination and a negative KOH preparation. 4, 5, 6
RESULTS
Study 1. In the Kose study 50 patients with recurrent and/or extensive tinea versicolor
were enrolled, and all 50 completed the treatment. They all had a positive KOH preparation and
Wood’s lamp examination. They had not received any topical antifungal treatment for two weeks
prior and no systemic antifungal treatment prior to this study. They were broken down randomly
into two groups: the treatment group which received itraconazole 400mg one dose and the
comparison group which received itraconazole 200mg/d for seven days. The patients were
evaluated clinically and mycologically before treatment began, at three weeks, and at six weeks
which was the end of the study. Clinically they received a grade based on the scaling,
hyper/hypopigmentation, and pruritis. They were scored 0=absent, 1= mild, 2= moderate, 3=
severe. The mycological evaluation included KOH preparation and Wood’s lamp examination,
and these were performed at each visit as well. At the end of the six weeks it was found that
there was no difference between the two regimens both clinically and mycologically in clearing
the tinea versicolor. The group that received one day of itraconazole had an 82% clinical cure
rate while the group receiving seven days of itraconazole had an 84% clinical cure rate.6 Table 2
summarizes the results for the Kose study, including a p-value of >0.05 indicating that the study
may not be statistically significant. NNT shows a value of -50 which can be interpreted as having
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to treat 50 people in order for one less beneficial outcome to occur compared to the control
group.
Table 2: Kose Study: Itraconazole 400mg x 1 dose vs. Itraconazole 200mg/d x 7 days
CER (7 days)

EER (1 day)

0.84

0.82

RBI
-0.02

ABI
-0.02

NNT
-50

p-value
>0.05

Study 2. The Wahab study evaluated the same dosages of itraconazole as was done in the
Kose study, and it was published eight years later. They had 60 patients who were all clinically
diagnosed with tinea versicolor by KOH preparation and Wood’s lamp examination. They were
broken down randomly into two groups: the treatment group which received itraconazole 400mg
for one dose and the comparison group which received itraconazole 200mg/d for seven days. The
patients were evaluated four weeks and eight weeks after the start of treatment. There were three
levels of clinical response: a cure was defined as complete clearing of the lesions, with negative
Wood’s lamp and KOH preparation, improvement was defined as maximum clearing of lesions
with or without negative Wood’s lamp and KOH preparation, and failure was defined as slight
improvement, unchanged or deteriorating without negative Wood’s lamp and KOH preparation.
This study had similar results to the prior study performed by Kose. At the end of the treatment
there was not a large difference between the two treatment groups in clearing the tinea
versicolor. In the group that received one day of itraconazole, 73% were cured and 17% were
improved. In the group that received seven days of itraconazole, 80% were cured and 13% were
improved.5 Table 3 summarizes the results for the Wahab study. A value of -15 for NNT means
that 15 people would need to be treated in order to achieve one less beneficial outcome.
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Table 3: Wahab study: Itraconazole 400mg x 1 dose vs. Itraconazole 200mg/d x 7 days
CER (7 days)

EER (1 day)

0.80

0.733

RBI
-0.084

ABI
-0.067

NNT
-15

p-value
Not reported

Study 3. The final study by Faergemann was a double blind RCT which included 238
patients with tinea versicolor who received an open treatment of itraconazole 200mg/d for seven
days. The following four weeks they did not receive any treatment. After the four weeks were
over, they returned to move onto the prophylactic treatment. Twenty-nine patients did not return
for the second phase. The remaining patients were tested with light microscopy to make sure
they were mycologically negative for tinea versicolor before continuing on with treatment. The
patients were randomly assigned to two groups for the double blind prophylactic treatment.
Group 1 received itraconazole 200mg BID one day per month for six months, and group 2
received placebo pills BID one day per month for six months. Findings were scored as either
cured, marked improvement, moderate improvement, unchanged, or deteriorated. When patients
subjectively scored the variables at the end of the treatment, including hypopigmentation,
pruritis, and erythema, they were significantly higher in the itraconazole group compared to the
placebo group. At the end of the prophylactic phase, 88% of patients in the itraconazole group
were still mycologically negative and 57% of patients in the placebo group were still
mycologically negative.4 Table 4 summarizes the results for the Faergemann study, including a
p-value of <0.001 indicating that the study was statistically significant. NNT in this study is 4,
meaning that 4 people need to be treated with the regimen in the study to have one more
beneficial outcome.
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Table 4: Faergemann study: Itraconazole 200mg vs placebo BID 1d/month x 6 months
CER

EER

(placebo)

(itraconazole)

0.566

0.88

RBI

0.555

ABI

0.314

NNT

4

p-value

<0.001

Safety and adverse events. In the Kose and Wahab studies, a complete blood count, liver
function tests, and renal function tests were checked for each patient before they started the
treatment. At week three of treatment, the patients in the Kose study were retested and had no
abnormalities in their blood work. All three studies reported adverse events in some of the
patients. In the Kose study five patients had adverse effects including fatigue, nausea, and
abdominal pain.6 In the Wahab study five patients complained of dyspepsia, nausea, and
flatulence.5 In the Faergemann study 26 patients reported adverse effects during open treatment
and 31 patients during the prophylactic phase. One patient experienced urticaria during the open
phase and was withdrawn from the study. Other patients experienced mild adverse effects
including gastrointestinal complaints in the open phase, while during the prophylactic phase
some patients encountered upper respiratory tract infections and influenza like symptoms.4
DISCUSSION
The goal of this systematic review was to determine whether or not itraconazole was
effective in treating tinea versicolor and if so, what the optimal dosage is. All three of the studies
demonstrated the effectiveness of itraconazole in treating tinea versicolor both clinically and
mycologically. There were some limitations of the studies due to the fact that only one of them
was double blinded. Also the studies did not mention if the patients were required to report to the
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hospital each time they received a dose of medication, therefore treatment adherence may have
been a complication and skewed the results. Patients that were required to take the medication
for seven days may have not been compliant with the regimen compared to the patients that only
had to take a single dose of itraconazole.
There were restrictions in these three studies due to the fact that the majority of patients
were men. In the Kose study, 37 patients were male and 13 were female.6 In the Wahab study, 53
patients were male and 7 were female.5 In the Faergemann study, 116 patients were male and 93
were female.4 The studies excluded pregnant females and females of child bearing age who did
not have access to contraception. This may be because itraconazole is a pregnancy category C
drug meaning that animal studies have shown an adverse effect on the fetus but there are no
adequate, well-controlled studies in humans.7 These three studies also were limited based on age
because they did not include children less than 18 years old in two of the studies and less than 12
years old in the third study, therefore the results may not be applicable to children. In the Kose
and Wahab studies, the mean duration that the patients had the tinea versicolor infection was
approximately 2-3 months, therefore the results may not be applicable to patients that have had a
tinea versicolor infection for a longer period of time. Lastly, race was not mentioned in the Kose
and Wahab studies, but in the Faergemann study it showed that the majority of patients were
Caucasian, with Asians being the next predominant race. Thus, the results may not be relevant
for patients of other races.
Itraconazole is similar in price as other antifungals and is available as a generic
prescription, so price should not be a concern for patients. It is also used to treat various fungal
infections such as aspergillosis, histoplasmosis, candidiasis, onychomycosis in both HIV infected
and non-HIV infected patients. The most common adverse effect of itraconazole is nausea.
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Patients may also experience diarrhea, vomiting, headache, rash, elevated liver function tests,
pruritis, dizziness, fatigue, hypertension, hypokalemia, etc. There is also a black box warning for
the use of itraconazole in a patient with congestive heart failure or any ventricular dysfunction.7
CONCLUSION
In conclusion, all of the studies showed that itraconazole is effective in treating tinea
versicolor. In the Kose and Wahab studies, it was demonstrated that a single dose of itraconazole
400mg is an effective alternative therapy to itraconazole 200mg for seven days. Using a single
dose treatment would be more advantageous because it would be less expensive and there would
not be problems with compliance as there may be with a seven day regimen. In the Faergemann
study it was shown that itraconazole is also effective as prophylaxis for tinea versicolor. Further
studies are warranted to prove the effectiveness of itraconazole as prophylaxis for a time period
longer than six months, as was done in the Faergemann study. Also further studies should
include double blinding, larger research groups, more female patients, various races, and a wider
age distribution to include children and geriatric patients. Based on the information obtained
from these three studies and the potential for future explorations, itraconazole has the potential to
become a first line medication for both the treatment of and prophylaxis for tinea versicolor.

References
1. Papadakis M, McPhee S, Rabow M. Current medical diagnosis & treatment. 2015th ed.
McGraw- Hill Education; 2014.
2. Burkhart C. Tinea Versicolor. Medscape. Available at
http://emedicine.medscape.com/article/1091575-clinical. Updated July 21, 2014.
Accessed December 4, 2014.
3. Mellen LA, Vallee J, Feldman SR, Fleischer AB. Treatment of pityriasis versicolor in the
United States. PubMed. Available at http://www.ncbi.nlm.nih.gov/pubmed/15204154.
Published June 15, 2004. Accessed December 4, 2014.
4. Faergemann J, Gupta AK, Al Mofadi A, Abanami A, Shareaah AA, Marynissen G.
Efficacy of itraconazole in the prophylactic treatment of pityriasis (tinea) versicolor. Arch
Dermatol. 2002; 138 (1): 69-73.
5. Wahab MA, Ali ME, Rahman MH, et al. Single dose (400mg) versus 7day (200mg) daily
dose itraconazole in the treatment of tinea versicolor: A randomized trial. Mymensingh
Med J. 2010; 9 (1): 72-76.
6. Kose O, Bulent Tastan H, Riza Gur A, Kurumlu Z. Comparison of a single 400mg dose
versus a 7-day 200mg daily dose of itraconazole in the treatment of tinea versicolor. J
Dermatolog Treat. 2002; 13 (2): 77-79.
7. Itraconazole (Rx). Medscape. Available at:
http://reference.medscape.com/drug/sporanox-omnel-itraconazole-342591#6. Accessed
December 4, 2014.

